Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | Ca.HO4P |
| Molecular Weight | 136.057 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Ca++].OP([O-])([O-])=O
InChI
InChIKey=FUFJGUQYACFECW-UHFFFAOYSA-L
InChI=1S/Ca.H3O4P/c;1-5(2,3)4/h;(H3,1,2,3,4)/q+2;/p-2
| Molecular Formula | Ca |
| Molecular Weight | 40.078 |
| Charge | 2 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | HO4P |
| Molecular Weight | 95.9793 |
| Charge | -2 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: http://www.globalrph.com/calcium_supplements.htm | https://www.ncbi.nlm.nih.gov/pubmed/26265479https://www.drugs.com/inactive/calcium-phosphate-dibasic-anhydrous-463.htmlhttp://apps.who.int/iris/bitstream/10665/43579/1/9789241530729_eng.pdfCurator's Comment: description was created based on several sources, including
https://www.alfa.com/en/catalog/043674/
Sources: http://www.globalrph.com/calcium_supplements.htm | https://www.ncbi.nlm.nih.gov/pubmed/26265479https://www.drugs.com/inactive/calcium-phosphate-dibasic-anhydrous-463.htmlhttp://apps.who.int/iris/bitstream/10665/43579/1/9789241530729_eng.pdf
Curator's Comment: description was created based on several sources, including
https://www.alfa.com/en/catalog/043674/
Calcium iodide (chemical formula CaI2) is the ionic compound of calcium and iodine, used in cat food as a source of iodine This colourless deliquescent solid is a salt that is highly soluble in water. Calcium iodide properties are similar to those for related salts, such as calcium chloride. Calcium iodide is also used in photography.
Originator
Approval Year
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Palliative | Unknown Approved UseUnknown |
|||
| Palliative | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseHypocalcemia, chronic (treatment) — Oral calcium supplements provide a source of calcium ion for treating calcium depletion occurring in conditions such as chronic hypoparathyroidism, pseudohypoparathyroidism, osteomalacia, rickets, chronic renal failure, and hypocalcemia secondary to the administration of anticonvulsant medications. When chronic hypocalcemia is due to vitamin D deficiency, oral calcium salts may be administered concomitantly with vitamin D analogs. However, calcium phosphate should not be used in patients with hypoparathyroidism or renal failure, since phosphate levels may be too high and giving more phosphate would exacerbate the condition. Calcium supplements should not be used in hyperparathyroidism, unless the need for a calcium supplement is high and the patient is carefully monitored. For treatment of hypocalcemia, supplementation is preferred |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Studies on the calcemic effect of intravenous secretin in humans. | 1975 Jun |
|
| Expression and functional analysis of chemokine receptors in human peripheral blood leukocyte populations. | 2001 Apr 7 |
|
| Endothelin-induced changes of secondary messengers in cultured corneal endothelial cells. | 2001 Aug |
|
| Metal ion-independent association of factor VIII subunits and the roles of calcium and copper ions for cofactor activity and inter-subunit affinity. | 2001 Aug 28 |
|
| Complement activation in factor D-deficient mice. | 2001 Dec 4 |
|
| Functional expression and characterization of a voltage-gated CaV1.3 (alpha1D) calcium channel subunit from an insulin-secreting cell line. | 2001 Jul |
|
| Aluminum toxicity alters the regulation of calbindin-D28k protein and mRNA expression in chick intestine. | 2001 Jul |
|
| Analysis of the native quaternary structure of vanilloid receptor 1. | 2001 Jul 27 |
|
| Endothelin- and sarafotoxin-induced receptor-mediated calcium mobilization in a clonal murine osteoblast-like cell line, MC3T3-E1/B. | 2001 Jun |
|
| [Acute renal failure caused by hypercalcemia]. | 2001 Jun 10 |
|
| Histamine induces exocytosis and IL-6 production from human lung macrophages through interaction with H1 receptors. | 2001 Mar 15 |
|
| RGS4 inhibits platelet-activating factor receptor phosphorylation and cellular responses. | 2001 Mar 27 |
|
| Oxidative impairment in scrapie-infected mice is associated with brain metals perturbations and altered antioxidant activities. | 2001 Nov |
|
| Activating mutations of the calcium-sensing receptor: management of hypocalcemia. | 2001 Nov |
|
| Molecular cloning and functional characterization of murine cysteinyl-leukotriene 1 (CysLT(1)) receptors. | 2001 Nov 1 |
|
| Hypoxia-induced regulation of MAPK phosphatase-1 as identified by subtractive suppression hybridization and cDNA microarray analysis. | 2001 Nov 30 |
|
| Microarray analysis of differential gene expression in lead-exposed astrocytes. | 2001 Oct 1 |
|
| Replacement of the muscle-specific sarcoplasmic reticulum Ca(2+)-ATPase isoform SERCA2a by the nonmuscle SERCA2b homologue causes mild concentric hypertrophy and impairs contraction-relaxation of the heart. | 2001 Oct 26 |
|
| Regional differences in functional receptor distribution and calcium mobilization in the intact human lens. | 2001 Sep |
|
| Effects of vitamin D receptor inactivation on the expression of calbindins and calcium metabolism. | 2001 Sep |
|
| Ameliorative effect of vasopressin-(4-9) through vasopressin V(1A) receptor on scopolamine-induced impairments of rat spatial memory in the eight-arm radial maze. | 2001 Sep 7 |
|
| Cannabinoids attenuate depolarization-dependent Ca2+ influx in intermediate-size primary afferent neurons of adult rats. | 2002 |
|
| Interaction of intravenous anesthetics with recombinant human M1-M3 muscarinic receptors expressed in chinese hamster ovary cells. | 2002 Dec |
|
| Mediation of unusually high concentrations of 1,25-dihydroxyvitamin D in homozygous klotho mutant mice by increased expression of renal 1alpha-hydroxylase gene. | 2002 Feb |
|
| Prostaglandin E(2) protects intestinal tumors from nonsteroidal anti-inflammatory drug-induced regression in Apc(Min/+) mice. | 2002 Jan 15 |
|
| Characterization of the bone-resorptive effect of interleukin-11 in cultured mouse calvarial bones. | 2002 Jul |
|
| Delayed asystolic cardiac arrest after diltiazem overdose; resuscitation with high dose intravenous calcium. | 2002 Jul |
|
| Transcriptional induction of CYP1A1 by oltipraz in human Caco-2 cells is aryl hydrocarbon receptor- and calcium-dependent. | 2002 Jul 5 |
|
| Human kidney diamine oxidase: heterologous expression, purification, and characterization. | 2002 Jun |
|
| Expression of functional CCR and CXCR chemokine receptors in podocytes. | 2002 Jun 15 |
|
| Investigation of a functional requirement for isoprenylation by the human prostacyclin receptor. | 2002 Mar |
|
| Hypertension-related intermyocyte junction remodelling is associated with a higher incidence of low-K(+)-induced lethal arrhythmias in isolated rat heart. | 2002 Mar |
|
| Alpha(1H) mRNA in single skeletal muscle fibres accounts for T-type calcium current transient expression during fetal development in mice. | 2002 Mar 15 |
|
| Diacylglycerol activates the influx of extracellular cations in T-lymphocytes independently of intracellular calcium-store depletion and possibly involving endogenous TRP6 gene products. | 2002 May 15 |
|
| Neuronal apoptosis inhibitory protein: Structural requirements for hippocalcin binding and effects on survival of NGF-dependent sympathetic neurons. | 2002 Nov 4 |
|
| Molecular cloning and characterization of the human voltage-gated calcium channel alpha(2)delta-4 subunit. | 2002 Sep |
|
| Inhibition of peroxisome proliferator-activated receptor (PPAR)-mediated keratinocyte differentiation by lipoxygenase inhibitors. | 2002 Sep 15 |
|
| Effects of endothelin B receptor agonists on amyloid beta protein (25-35)-induced neuronal cell death. | 2002 Sep 6 |
|
| A critical interplay between Ca2+ inhibition and activation by Mg2+ of AC5 revealed by mutants and chimeric constructs. | 2002 Sep 6 |
|
| Mechanism of enhanced calcium sensitivity and alpha 2-AR vasoreactivity in chronic NOS inhibition hypertension. | 2003 Jan |
|
| [Prevention of osteoporosis by foods and dietary supplements. Bioavailability of milk micellar calcium phosphate]. | 2006 Oct |
|
| Henri Moissan: winner of the Nobel Prize for Chemistry 1906. | 2006 Oct 20 |
|
| Dietary calcium source influences body composition, glucose metabolism and hormone levels in a mouse model of postmenopausal obesity. | 2009 Jul-Aug |
|
| A combination of calcium phosphate and probiotics beneficially influences intestinal lactobacilli and cholesterol metabolism in humans. | 2012 Apr |
|
| Effect of calcium phosphate and vitamin D₃ supplementation on bone remodelling and metabolism of calcium, phosphorus, magnesium and iron. | 2014 Jan 17 |
|
| Long-term remineralizing effect of casein phosphopeptide-amorphous calcium phosphate (CPP-ACP) on early caries lesions in vivo: a systematic review. | 2014 Jul |
|
| Efficacy and safety of inhaled calcium lactate PUR118 in the ozone challenge model--a clinical trial. | 2015 Aug 12 |
|
| Dietary interventions for mineral and bone disorder in people with chronic kidney disease. | 2015 Sep 16 |
|
| Lactose behaviour in the presence of lactic acid and calcium. | 2016 Aug |
|
| Effects of ultrasound treatment on physico-chemical, functional properties and antioxidant activity of whey protein isolate in the presence of calcium lactate. | 2018 Mar |
Sample Use Guides
oral: 500 to 2000 mg elemental calcium a day, in divided doses (bid-qid).
inhalation: In a single-blind, phase 1B proof of concept study, 24 subjects were enrolled to sequentially receive three doses of PUR118 (calcium lactate inhalation powder (CLIP) formulation) (5.5 mg, n = 18; 11.0 mg, n = 18; 2.8 mg, n = 16). Each dose was inhaled 3 times (1, 13, 25 h, preceded by 2 puffs salbutamol) before the ozone exposure (250 ppb, 3 h intermittent exercise). Sputum was induced 3 h after the end of exposure.
Route of Administration:
Other
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 16 17:18:34 UTC 2022
by
admin
on
Fri Dec 16 17:18:34 UTC 2022
|
| Record UNII |
L11K75P92J
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
CODEX ALIMENTARIUS (GSFA) |
INS-341(II)
Created by
admin on Fri Dec 16 17:18:34 UTC 2022 , Edited by admin on Fri Dec 16 17:18:34 UTC 2022
|
||
|
JECFA EVALUATION |
INS-341(II)
Created by
admin on Fri Dec 16 17:18:34 UTC 2022 , Edited by admin on Fri Dec 16 17:18:34 UTC 2022
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
24441
Created by
admin on Fri Dec 16 17:18:34 UTC 2022 , Edited by admin on Fri Dec 16 17:18:34 UTC 2022
|
PRIMARY | |||
|
47627
Created by
admin on Fri Dec 16 17:18:34 UTC 2022 , Edited by admin on Fri Dec 16 17:18:34 UTC 2022
|
PRIMARY | |||
|
L11K75P92J
Created by
admin on Fri Dec 16 17:18:34 UTC 2022 , Edited by admin on Fri Dec 16 17:18:34 UTC 2022
|
PRIMARY | |||
|
DICALCIUM PHOSPHATE
Created by
admin on Fri Dec 16 17:18:34 UTC 2022 , Edited by admin on Fri Dec 16 17:18:34 UTC 2022
|
PRIMARY | |||
|
ANHYDROUS DIBASIC CALCIUM PHOSPHATE
Created by
admin on Fri Dec 16 17:18:34 UTC 2022 , Edited by admin on Fri Dec 16 17:18:34 UTC 2022
|
PRIMARY | Description: A white or almost white powder; odourless. Solubility: Practically insoluble in cold water and ethanol (~750 g/l) TS; soluble in dilute acids. Category: Tablet and capsule diluent. Storage: Calcium hydrogen phosphate should be kept in a well-closed container. Labelling: The designation on the container of Calcium hydrogen phosphate should state whether it is the dihydrate or the anhydrous form. Requirement: Calcium hydrogen phosphate contains not less than 30.9% and not more than the equivalent of 31.7% of calcium, Ca, calculated with reference to the ignited substance. | ||
|
INS-341(II)
Created by
admin on Fri Dec 16 17:18:34 UTC 2022 , Edited by admin on Fri Dec 16 17:18:34 UTC 2022
|
PRIMARY | |||
|
L11K75P92J
Created by
admin on Fri Dec 16 17:18:34 UTC 2022 , Edited by admin on Fri Dec 16 17:18:34 UTC 2022
|
PRIMARY | |||
|
DBSALT002430
Created by
admin on Fri Dec 16 17:18:34 UTC 2022 , Edited by admin on Fri Dec 16 17:18:34 UTC 2022
|
PRIMARY | |||
|
32596
Created by
admin on Fri Dec 16 17:18:34 UTC 2022 , Edited by admin on Fri Dec 16 17:18:34 UTC 2022
|
PRIMARY | |||
|
4496
Created by
admin on Fri Dec 16 17:18:34 UTC 2022 , Edited by admin on Fri Dec 16 17:18:34 UTC 2022
|
PRIMARY | |||
|
C77523
Created by
admin on Fri Dec 16 17:18:34 UTC 2022 , Edited by admin on Fri Dec 16 17:18:34 UTC 2022
|
PRIMARY | |||
|
M2964
Created by
admin on Fri Dec 16 17:18:34 UTC 2022 , Edited by admin on Fri Dec 16 17:18:34 UTC 2022
|
PRIMARY | Merck Index | ||
|
CHEMBL2107567
Created by
admin on Fri Dec 16 17:18:34 UTC 2022 , Edited by admin on Fri Dec 16 17:18:34 UTC 2022
|
PRIMARY | |||
|
231-826-1
Created by
admin on Fri Dec 16 17:18:34 UTC 2022 , Edited by admin on Fri Dec 16 17:18:34 UTC 2022
|
PRIMARY | |||
|
992
Created by
admin on Fri Dec 16 17:18:34 UTC 2022 , Edited by admin on Fri Dec 16 17:18:34 UTC 2022
|
PRIMARY | |||
|
DTXSID20872529
Created by
admin on Fri Dec 16 17:18:34 UTC 2022 , Edited by admin on Fri Dec 16 17:18:34 UTC 2022
|
PRIMARY | |||
|
C1505
Created by
admin on Fri Dec 16 17:18:34 UTC 2022 , Edited by admin on Fri Dec 16 17:18:34 UTC 2022
|
CONCEPT | Dietary Supplement | ||
|
SUB16368MIG
Created by
admin on Fri Dec 16 17:18:34 UTC 2022 , Edited by admin on Fri Dec 16 17:18:34 UTC 2022
|
PRIMARY | |||
|
253163
Created by
admin on Fri Dec 16 17:18:34 UTC 2022 , Edited by admin on Fri Dec 16 17:18:34 UTC 2022
|
ALTERNATIVE | |||
|
SUB11772MIG
Created by
admin on Fri Dec 16 17:18:34 UTC 2022 , Edited by admin on Fri Dec 16 17:18:34 UTC 2022
|
PRIMARY | |||
|
7757-93-9
Created by
admin on Fri Dec 16 17:18:34 UTC 2022 , Edited by admin on Fri Dec 16 17:18:34 UTC 2022
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
SOLVATE->ANHYDROUS | |||
|
SOLVATE->ANHYDROUS |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
||
|
|
ACTIVE MOIETY |
|
